Mostrar el registro sencillo

dc.contributor.authorEvers, Stefan
dc.contributor.authorDell'Agnello, Grazia
dc.contributor.authorNovick, Diego
dc.contributor.authorGonderten, H. Saygin
dc.contributor.authorPanni, Tommaso
dc.contributor.authorPascual Gómez, Julio 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-06-11T15:41:04Z
dc.date.available2024-06-11T15:41:04Z
dc.date.issued2024
dc.identifier.issn2193-8237
dc.identifier.issn2193-651X
dc.identifier.urihttps://hdl.handle.net/10902/33031
dc.description.abstractIntroduction: The ObserVational survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) European Union (EU) is part of an overarching population-based study program that also includes the United States and Japan. Here, we report data on the migraine/severe headache burden and the use of acute medication and healthcare resources in Spain and Germany. Methods: OVERCOME (EU) was an online, non-interventional, cross-sectional survey conducted in adults in Spain and Germany between October 2020 and February 2021. A total migraine cohort was established based on health survey participants who reported headache/migraine in the last 12 months AND identified as having migraine based on modified International Classification of Headache Disorders, third edition criteria OR self-reported physician diagnosis. Data were analyzed for the total migraine cohort and the subcohort with moderate to severe headache attacks, with average pain severity ≥5 points, pain duration ≥4 h, and at least moderate disability due to migraine [Migraine Disability Assessment (MIDAS) score ≥11] over the past 3 months. Results: Pain of moderate or severe intensity was the most frequent symptom in the total migraine cohort (n = 19,103/20,756; 92.0%). Proportions of participants reporting severe disability (MIDAS Grade IV), poorer quality of life (QoL; Migraine-Specific QoL Questionnaire), and higher interictal burden (Migraine Interictal Burden Scale-4), generally increased with number of headache days (HDs)/month. Most participants (92.5%) reported current acute migraine/severe headache medication use, although only 39.0% were using triptans. In the moderate to severe attacks subcohort (n = 5547), 48.4% were using triptans, with nonsteroidal anti-inflammatory drugs the most common acute medication. The moderate to severe attacks subcohort also reported poorer QoL and greater pain and disability with increasing HDs/month, although severe interictal burden was reported for ~ 60% of participants regardless of HDs/month. Treatment satisfaction (six-item migraine Treatment Optimization Questionnaire) in those using triptans was generally poor in both total and subcohorts. Conclusion: High migraine-related burden levels were reported, despite use of acute medication. Although triptans are recommended for moderate to severe migraine attacks in Spanish and German guidelines, less than half of participants were using triptans; treatment satisfaction in those using triptans was generally poor. New tailored treatment options may help address unmet needs in current acute treatment.es_ES
dc.description.sponsorshipFunding. This study and Rapid service fee was funded by Eli Lilly and Company. ACKNOWLEDGEMENTS: The authors would like to thank the participants of this study for their time and important contributions.es_ES
dc.format.extent19 p.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Healthcarees_ES
dc.rights© The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourcePain and Therapy, 2024, 13, 589-607es_ES
dc.subject.otherMigrainees_ES
dc.subject.otherSevere headachees_ES
dc.subject.otherMigraine symptomses_ES
dc.subject.otherBurden of migrainees_ES
dc.subject.otherAcute treatment patternses_ES
dc.subject.otherTreatment satisfactiones_ES
dc.titleAcute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1007/s40122-024-00589-3es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1007/s40122-024-00589-3
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.Excepto si se señala otra cosa, la licencia del ítem se describe como © The Author(s) 2024. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.